Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC sunscreens rule

This article was originally published in The Tan Sheet

Executive Summary

FDA will continue to accept comments on its proposed rule to amend the final monograph for over-the-counter sunscreen products until Dec. 26, the agency announces in a Nov. 28 Federal Register notice. The agency pushed the deadline back by one month in response to requests from parties wanting additional time to submit comments. FDA issued the proposed rule Aug. 23, amending the final monograph to include UVA ray protection standards including in vivo and in vitro tests (1"The Tan Sheet" Aug. 27, 2007, p. 3). The final monograph was issued in 1999, but has consistently been stayed due to pressure from industry...

You may also be interested in...



Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity

FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.

UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027

The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel